BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cascales-campos P, Ramírez P, Lopez V, Gonzalez R, Saenz-mateos L, Llacer E, Sánchez Bueno F, Robles R, Pons J, Capel A, Frutos L, Navarro J, Muñoz-ramon P, Parrilla P. Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation. Transplantation Proceedings 2015;47:2374-6. [DOI: 10.1016/j.transproceed.2015.08.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Cascales-campos PA, Romero PR, Schneider MA, Lopez-lopez V, Navarro JL, Frutos L, Pons Miñano JA, Paricio PP. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? European Journal of Radiology 2017;91:155-9. [DOI: 10.1016/j.ejrad.2017.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Gerke O, Ehlers K, Motschall E, Høilund-Carlsen PF, Vach W. PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues. Mol Imaging Biol 2020;22:33-46. [PMID: 31016638 DOI: 10.1007/s11307-019-01351-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Ali SA, Amin DH, Abdelkhalek YI. Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. Jpn J Radiol 2020;38:472-9. [PMID: 32078123 DOI: 10.1007/s11604-020-00930-8] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sánchez-Lorencio MI, Saenz L, Ramirez P, Villalba-López F, de la Orden V, Mediero-Valeros B, Revilla Nuin B, Gonzalez MR, Cascales-Campos PA, Ferreras-Martínez D, Noguera-Velasco JA, Díaz-Rubio E, Parrilla P. Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients. Transplant Proc 2018;50:623-7. [PMID: 29579870 DOI: 10.1016/j.transproceed.2017.11.061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ramirez P, Sáenz L, Cascales-campos P, González Sánchez M, Llàcer-millán E, Sánchez-lorencio M, Díaz-rubio E, De La Orden V, Mediero-valeros B, Navarro J, Revilla Nuin B, Baroja-mazo A, Noguera-velasco J, Sánchez B, de la Peña J, Pons-miñano J, Sánchez-bueno F, Robles-campos R, Parrilla P. Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation. Transplantation Proceedings 2016;48:2962-5. [DOI: 10.1016/j.transproceed.2016.07.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Ding E, Lu D, Wei L, Feng X, Shen J, Xu W. Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma. Oncol Lett 2020;20:1245-55. [PMID: 32724365 DOI: 10.3892/ol.2020.11681] [Reference Citation Analysis]
10 Sharma R, Inglese M, Dubash S, Lu H, Pinato DJ, Sanghera C, Patel N, Chung A, Tait PD, Mauri F, Crum WR, Barwick TD, Aboagye EO. Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using 18F-Fluorothymidine PET. J Nucl Med 2020;61:1743-8. [PMID: 32513905 DOI: 10.2967/jnumed.119.240598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]